Most recent update: Tuesday, December 12, 2017 - 16:38

Bariatric News - Cookies & privacy policy

You are here

EndoBarrier Therapy

EndoBarrier’s effect on glucose control and bile acid regulators

EndoBarrier Therapy led to an improvement in multiple glycaemic parameters and a sustained decrease in body weight and body fat
EndoBarrier Therapy also raised levels of the incretin hormone GLP-1

Data showing the effect of EndoBarrier Therapy on bile acid regulators and other anthropometric, biochemical and hormonal parameters has been revealed by Professor Martin Haluzik of the IKEM Research Centre Prague, Czech Republic, during the 75th Annual Meeting of the American Diabetes Association in Boston, MA.

Haluzik’s presentation, ‘Ten Months of Treatment with Endoscopic Duodenal-jejunal Bypass Liner Reduces Glycemic Variability, Increases Serum Fibroblast Growth Factor 19 (FGF-19), and Partially Restores the Incretin Effect in Obese Subjects with Type 2 Diabetes Mellitus,’ reported that outcomes from 30 obese patients with type 2 diabetes after being implanted with the EndoBarrier gastrointestinal liner.

The study results show that EndoBarrier Therapy led to an improvement in multiple glycaemic parameters and a sustained decrease in body weight and body fat. Notably, fibroblast growth factor 19 (FGF-19), a potent regulator of bile acid, glucose and fat metabolism, was markedly increased by EndoBarrier Therapy. In addition, EndoBarrier Therapy also raised levels of the incretin hormone GLP-1.

“The positive effects of EndoBarrier Therapy on glycemia, body weight and body fat are well documented. However, this data shows that EndoBarrier Therapy also elevates FGF-19 levels – a naturally occurring protein that is thought to be involved in bile acid synthesis and more general metabolic homeostasis,” ” said Dr David Maggs, chief medical officer of GI Dynamics. “More specifically, FGF-19 is active in a specific metabolic axis that has drawn recent attention as a putative pharmacological target for the treatment of fatty liver disease.”

The EndoBarrier is the first endoscopically-delivered device therapy approved for the treatment of obese type 2 diabetes with BMI≥30 or obese patients with BMI≥30 with ≥1 comorbidities or obese patients with BMI >35. The liner is indicated for a maximum implant duration of 12 months. EndoBarrier is approved and commercially available in multiple countries outside the US. EndoBarrier is not approved for sale in the US and is limited by federal law to investigational use only in the US. GI Dynamics is conducting a pivotal clinical trial of EndoBarrier in the US for the treatment of patients who have uncontrolled type 2 diabetes and are obese. 

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.